Finance
Analyst’s Sets Eli Lilly and Company (NYSE:LLY) New Target at $216.36: LLY is Now On A Buy List
Eli Lilly and Company (NYSE:LLY) has a beta of 0.24, a 12-month trailing P/E ratio of 32.73, and a growth ratio of 2.56. The stock’s
Eli Lilly and Company (NYSE:LLY) has a beta of 0.24, a 12-month trailing P/E ratio of 32.73, and a growth ratio of 2.56. The stock’s
Eli Lilly and Company (NYSE:LLY) Relative Strength Index (RSI) is 70.27, with weekly volatility at 2.94% and ATR at 6.27. The LLY stock’s 52-week price
Eli Lilly and Company (NYSE:LLY) has a beta of 0.25, a 12-month trailing P/E ratio of 30.26, and a growth ratio of 2.39. The stock’s
Eli Lilly and Company (NYSE:LLY) Relative Strength Index (RSI) is 62.17, with weekly volatility at 2.03% and ATR at 3.75. The LLY stock’s 52-week price
On Monday, Eli Lilly and Company (LLY) was up +11.74% to $185.94. Company’s Donanemab, an experimental antibody targeting a transformed type of beta-amyloid called N3pG,
Discover high-quality information at your convenience with ‘State Reviewer.’ Our news portal offers valuable insights for free, available in accessible locations such as metro stations, busy intersections, cafes, and business centers. Wherever your day takes you, ‘State Reviewer’ ensures you’re never out of touch with the latest news and updates.
All rights reserved © 2024, Powered by Smart TechOne